cAMP regulates vasopressin-induced AQP2 expression via protein kinase A-independent pathway  by Umenishi, Fuminori et al.
1758 (2006) 1100–1105
www.elsevier.com/locate/bbamemBiochimica et Biophysica ActacAMP regulates vasopressin-induced AQP2 expression via protein
kinase A-independent pathway
Fuminori Umenishi a,b,⁎, Takefumi Narikiyo a, Alain Vandewalle c, Robert W. Schrier a
a Department of Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA
b Department of Physiology and Biophysics, University of Colorado Health Sciences Center, Denver, CO 80262, USA
c INSERM U478, Faculte de Medecine Xavier Bichat, Paris, France
Received 5 October 2005; received in revised form 31 May 2006; accepted 1 June 2006
Available online 7 June 2006Abstract
The regulation of AVP-induced AQP2 expression was investigated in the present study. AVP administration induced AQP2 expression in a
dose-dependent manner in association with an increase in intracellular cAMP concentration. PKA activity was stimulated by AVP but PKA
inhibitors did not block the upregulation of AQP2 expression. However, AVP also activated both ERK and CREB pathways, and ERK inhibitor
attenuated the upregulation of AQP2 expression. These results therefore indicate that the effect of AVP stimulation to upregulate AQP2 expression
involves a PKA-independent pathway.
© 2006 Elsevier B.V. All rights reserved.Keywords: Aquaporin-2; Arginine vasopressin; cAMP; ERK; CREB; PKAThe regulation of water balance by the kidney is one of the
most fundamental homeostatic functions and is rigorously
controlled by arginine vasopressin (AVP). Aquaporin-2 (AQP2)
is exclusively expressed in the principal cells of the collecting
tubule and collecting duct and is known as the vasopressin-
regulated water channel [1,2]. Acute water reabsorption in the
kidney collecting duct is mediated by the trafficking of AQP2 to
the apical membrane from intracellular vesicles in response to
AVP [3–5]. In addition to this regulation on the short-term, the
long-term regulation of AQP2 expression plays an important
role in water reabsorption in the collecting duct. The regulation
of AQP2 by AVP involves upregulation of AQP2 transcription
via cAMP responsive element (CRE), which results in a
remarkable increase of AQP2 expression [6,7]. Further, it is
thought that AQP2 transcription is mediated by the phosphor-
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induced AQP2 expression have not been fully defined. To better
elucidate this process, a cell line expressing intact cis- and
trans-acting AQP2 is required. In this regard, an immortalized
mouse cortical collecting duct cell line mpkCCDC14 was used in
the present study. This cell line, which is derived from
microdissected cortical collecting ducts of an SVPK/Tag
transgenic mouse, exhibits most of the major functional
properties of collecting duct principal cells and natively
expresses AQP2 [8,9]. By using this cell line, the regulation
of AVP-induced AQP2 expression was investigated.
First, the reactivity and sensitivity of AVP to increase AQP2
expression was investigated. mpkCCDC14 cells were seeded on
transwell chambers with permeable support. After confluence,
cells were exposed to serum-free medium with no growth
factors for 24 h before use. Then, the cells were incubated with
different concentrations of AVP. After 24 h of incubation, AQP2
protein expression was investigated by immunoblot analysis.
As shown in Fig. 1A, AQP2 protein bands were detected as
non-glycosylated, core-glycosylated, and fully glycosylated
forms. AVP-induced AQP2 expression was observed at the
concentration of 10−11 M and increased in a dose-dependent
Fig. 1. (A) AQP2 expression is increased in an AVP dose-dependent manner in mpkCCDC14 cells. Cells grown on Transwell chambers with permeable support were
incubated with serum-free medium with no growth factors for 24 h before use. Cells were incubated with different concentrations of AVP (10−12 to 10−8 M) for 24 h.
AVP was added to the basolateral side. Then, cells were washed with ice-cold PBS, suspended with 20 mM Tris (pH 7.5) containing 150 mM NaCl, 1% Triton X-100
and protease inhibitor cocktail, and incubated for 30 min on ice. After centrifuged at 14,000×g for 10 min at 4 °C, the supernatant was collected, and protein
concentration was measured using the Bradford protein assay method. The cell extract was resolved on a 12% SDS-polyacrylamide gel and transferred to a PVDF
membrane. The membrane was incubated with a polyclonal anti-AQP2 antibody. After washing, the membrane was incubated with anti-rabbit IgG horseradish
peroxidase secondary antibody. The immunoreactive bands were visualized by enhanced chemiluminescence method. AQP2 protein bands were detected as non-
glycosylated (ng-AQP2), core-glycosylated (cg-AQP2), and fully glycosylated (g-AQP2) forms. The bands on the film were scanned and analyzed by using the NIH
image software. To confirm that equal amounts of protein samples were loaded, duplicate gels were stained with Coomassie Brilliant Blue (data not shown). AQP2
expression in basal medium was assigned as 1-fold. Values represent the mean±SE of three independent sets of experiments. (B) V2R, but not V1R, antagonist blocks
AVP-induced AQP2 expression. Cells were pretreated without or with V1R antagonist ([β-mercapto-β,β-cyclopentamethylenepropionyl
1, O-me-Tyr2, Arg8]-
vasopressin; 1 μM) or V2R antagonist ([adamantaneacetyl
1, O-Et-D-Tyr2, Val4, aminobutyryl6, Arg8,9]-vasopressin; 1 μM) for 30 min and then incubated without or
with AVP (10−8 M) in the presence of antagonist for 24 h. Then, cells were harvested and total protein was analyzed by immunoblot. (C) AQP2 expression is regulated
by increased intracellular cAMP concentration. Cells grown on Transwell chambers with permeable support were incubated with different concentrations of forskolin
(1 or 10 μM) or 8-(4-chloro-phenylthio)-3′,5′-cyclicmonophosphate (8CPT-cAMP; 1, 10, or 100 μM) for 24 h. The cells were then harvested and total protein was
analyzed by immunoblot.
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10−8 M AVP. This induction was shown when AVP was added
only to the basolateral membrane side, but not the apical side.
Further, there was no AQP2 induction in cells cultured on a
plastic dish (data not shown). Thus, AQP2 expression is
increased in an AVP dose-dependent manner.
The results in Fig. 1A indicated that AQP2 expression was
associated with AVP action. In the collecting duct, AVP binds to
both its V1 and V2 receptors (V1R and V2R) located on the
basolateral membrane. The V1R and V2R elevate intracellular
Ca2+ via G protein-coupled phospholipase C/ inositol 3,4,5-
triphosphate signaling and cAMP via adenylyl cyclase,
respectively. Therefore, both vasopressin receptor antagonists
were tested whether they blocked AVP-induced AQP2 expres-
sion. The pretreatment with V2R, but not V1R, blocked AVP-
induced AQP2 expression (Fig. 1B). Further, phospholipase C
inhibitor did not block AVP-induced AQP2 expression (data not
shown). This result therefore indicates that AVP-induced AQP2
expression is mediated via its V2R.The result in Fig. 1B suggested that AVP-induced AQP2
expression was associated with intracellular cAMP concentra-
tion. Therefore, cAMP analog 8CPT-cAMP and adenylyl
cyclase activator forskolin were tested whether they induced
AQP2 expression. As shown in Fig. 1C, both stimulators
strongly induced AQP2 expression in a dose-dependent manner.
This result indicates that AVP-induced AQP2 expression is
mediated by intracellular cAMP via V2R and the increase in
intracellular cAMP is critical for upregulation of AQP2
expression.
The result in Fig. 1C suggested that AQP2 expression was
associated with increased intracellular cAMP concentration.
Therefore, the intracellular cAMP concentration was measured
by ELISA. As expected, intracellular cAMP concentration was
increased in an AVP dose-dependent manner (Fig. 2A). Since
PKA is the principal target of cAMP, the PKA activity was
measured by using PKA substrate Kemptide. Similarly, PKA
activity was significantly increased when the cells were
incubated with AVP (Fig. 2B). The addition of forskolin to
Fig. 2. Measurement of intracellular cAMP concentration and PKA activity in
mpkCCDC14 cells. (A) Intracellular cAMP. Intracellular cAMP level was
measured using cAMP EIA kit (Cayman Chemical) according to the
manufacturer's instructions. Cells were incubated with different concentrations
of AVP (10−12 to 10−8 M) in the presence of 3-isobutyl-1-methylxanthine
(IBMX; 100 μM) for 30 min. IBMX was used as an inhibitor of cAMP
phosphodiesterase. Intracellular cAMP was extracted with 150 μl of 0.1 N HCl
at room temperature for 20 min. Cells were scraped off and cell protein content
was measured by the Bradford protein assay. cAMP concentration was
expressed in picomoles per microgram protein. Values represent the mean±SE
of three independent sets of experiments. (B) PKA activity. Cells were incubated
with different concentrations of AVP (10−10 to 10−8 M) or forskolin (FK; 10 μM)
in the presence of IBMX (100 μM) for 30 min. Then, cells were lysed in a buffer
containing 50 mM β-glycerophosphate (pH 7.2), 0.1 mM sodium orthovana-
date, 0.5% Triton X-100, 2 mM MgCl2, 1 mM EGTA, 1 mM dithiothreitol,
100 μg/ml aprotinin, and 100 μg/ml leupeptin. The lysates were incubated with a
reaction buffer containing 20 mMMOPS (pH 7.2), 25 mM β-glycerophosphate,
5 mM EGTA, 1 mM sodium orthovanadate, 1 mM dithiothreitol, 12.5 mM
MgCl2, 0.1 mM ATP, 200 μM Kemptide as a substrate peptide and 10 μCi of
[γ-32P]ATP (3,000 Ci/mmol). The phosphorylation reaction was performed for
10 min at 30 °C and then stopped by spotting on to Whatman P81 papers. The
papers were washed three times with 0.75% phosphoric acid, rinsed in acetone
and air dried. The radioactivity was determined by scintillation counter. PKA
activity was expressed in picomoles phosphate incorporated into Kemptide/min.
Each cell extract was assayed in the absence of cAMP to determine
endogenously activated PKA. Values represent the mean±SE of three
independent sets of experiments.
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that AVP can activate PKA in a cAMP dose-dependent manner.
Next, to investigate whether the activation of PKA was
involved in AVP-induced AQP2 expression, cells wereFig. 3. PKA inhibitors do not block AVP-induced AQP2 expression. Cells were
pretreated without or with PKA inhibitor Rp-adenosine 3′,5′-monophosphor-
othioate (Rp-cAMP; 10 or 20 μM) or N-[2-(p-bromocinnamylamino)ethyl]-5-
isoquinolinesulfonamide (H89; 10 or 20 μM) for 30 min and then incubated
without or with AVP (10−8 M) in the presence of inhibitor for 24 h. Then, cells
were harvested and total protein was analyzed by immunoblot. Each protein blot
was analyzed by densitometry. AVP-induced AQP2 expression in the absence of
inhibitor was assigned as 100%. Values represent the mean±SE of three
independent sets of experiments.pretreated with different concentrations of PKA inhibitor Rp-
cAMP or H89 and then incubated with AVP for 24 h. As shown
in Fig. 3, AVP-induced AQP2 expression was not blocked by
either PKA inhibitor tested. Moreover, PKA peptide inhibitor
(14–22 amide) also had no effect on AVP-induced AQP2
expression (data not shown). This result indicates that AVP-
induced AQP2 expression is mediated by a PKA-independent
pathway.
Although it is thought that PKA is the main target of cAMP,
the above results indicate that PKA activation by increased
intracellular cAMP does not influence the regulation of AQP2
expression. It is known that AVP stimulates mitogen-activated
protein kinase (MAPK) pathway in many cell types [10,11].
Therefore, to investigate the possibility of the involvement of
MAPK pathway on AVP-induced AQP2 expression, extra-
cellular signal-regulated kinase (ERK), p38, and c-Jun NH2-
terminal kinase (JNK) inhibitors were tested. As shown in Fig.
4, only ERK inhibitor, U0126, blocked AVP-induced AQP2
expression; the decrease occurred in a dose-dependent manner.
However, p38 inhibitor SB203580 and JNK inhibitor SP600125
did not attenuate AVP-induced AQP2 expression. These data
indicate that AVP-induced AQP2 expression is mediated via
cAMP/ERK rather than cAMP/PKA signaling pathway.
The results in Fig. 4 indicated that AVP-induced AQP2
expression was dependent on ERK activation. Therefore, to
examine whether ERK pathway is activated by the addition of
AVP in this cell line, different concentrations of AVP were
tested. Indeed, ERK was activated by AVP in a dose-dependent
manner (Fig. 5A). Next, to investigate whether AVP-stimulated
ERK pathway is associated with PKA activation, cells were
pretreated with ERK or PKA inhibitor and then incubated with
AVP. The phosphorylation of ERK was examined by immuno-
blot. As shown in Fig. 5B, AVP-stimulated ERK activation was
completely blocked by ERK inhibitor U0126, but not by PKAFig. 4. AVP-induced AQP2 expression is attenuated by ERK inhibition. Cells
were pretreated without or with ERK inhibitor U0126 (1, 2.5, 5, or 10 μM), p38
inhibitor SB203580 (10 μM), or JNK inhibitor SP600125 (10 μM) for 30 min
and then incubated without or with AVP (10−8 M) in the presence of inhibitor for
24 h. Cells were harvested and total protein was analyzed by immunoblot. Each
protein blot was analyzed by densitometry. AVP-induced AQP2 expression in
the absence of inhibitor was assigned as 100%. Values represent the mean±SE
of three independent sets of experiments. *p<0.005 versus AVP-induced AQP2
expression.
Fig. 5. (A) Cells were incubated with different concentrations of AVP (10−12 to 10−8 M) for 15 min. Then, cells were solubilized in lysis buffer (50 mM
β-glycerophosphate, pH 7.2, 0.1 mM sodium orthovanadate, 0.5% Triton X-100, 2 mM MgCl2, 1 mM EGTA, 1 mM dithiothreitol, 100 μg/ml aprotinin, 100 μg/ml
leupeptin, and protein phosphatase inhibitor cocktail). Cell lysate was analyzed by immunoblot with phospho-ERK (p-ERK) and ERK antibodies. Each protein blot was
analyzed by densitometry. The ratio of p-ERK/ERK in basal conditions was assigned as 1-fold. (B) Cells were pretreated without or with PKA inhibitor Rp-cAMP
(20 μM) or ERK inhibitor U0126 (10 μM) for 30 min and then incubated without or with AVP (10−8 M) for 15 min. Cells were solubilized in lysis buffer and cell lysate
was analyzed by immunoblot with p-ERK and ERK antibodies. Each protein blot was analyzed by densitometry. The ratio of p-ERK/ERK in basal conditions was
assigned as 1-fold. (C) Cells were pretreated without or with PKA inhibitor Rp-cAMP (20 μM) or ERK inhibitor U0126 (10 μM) for 30 min and then incubated without
or with 8CPT-cAMP (1, 10, or 100 μM) for 15 min. Cells were solubilized in lysis buffer and cell lysate was analyzed by immunoblot with p-ERK and ERK antibodies.
Each protein blot was analyzed by densitometry. The ratio of p-ERK/ERK in basal conditions was assigned as 1-fold. (D) Cells were pretreated without or with PKA
inhibitor Rp-cAMP (20 μM) or H89 (20 μM) or ERK inhibitor U0126 (10 μM) for 30 min and then incubated without or with 8-(4-chlorophenylthio)-2′-O-
methyladenosine-3′,5′-cyclic monophosphate (8CPT-2Me-cAMP; 50 μM) for 15 min. Cells were solubilized in lysis buffer and cell lysate was analyzed by
immunoblot with p-ERK and ERK antibodies. Each protein blot was analyzed by densitometry. The ratio of p-ERK/ERK in basal condition was assigned as 1-fold.
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the cells stimulated ERK activation and PKA inhibitor Rp-
cAMP did not block cAMP-stimulated ERK phosphorylation
(Fig. 5C). These results provide further evidence that cAMP
activated ERK pathway and this effect is independent of PKA
pathway.
Recently, a new member of cAMP-dependent protein kinase
was discovered, namely exchange protein directly activated by
cAMP (Epac) [12,13]. It was hypothesized that this novel
cAMP-dependent protein kinase, Epac, was involved in AVP-
induced AQP2 expression. Therefore, it was investigated
whether the Epac specific activator 8CPT-2Me-cAMP influ-
enced the activation of ERK pathway in this cell. As shown in
Fig. 5D, this Epac activator indeed stimulated ERK pathway.
Both PKA inhibitors H89 and Rp-cAMP did not influence Epac
activator-stimulated ERK phosphorylation, whereas ERK
inhibitor U0126 completely blocked its phosphorylation.
Therefore, these results suggest that AVP activates cAMP/
Epac/ERK signaling cascade.
In the regulation of AQP2 expression, increased intracel-
lular cAMP upregulates AQP2 expression through a cAMP
response element (CRE) in the AQP2 gene [6,7]. The
activation of CRE binding protein (CREB) phosphorylation
is critical for upregulation of AQP2 transcription. In this
regard the CRE in the AQP2 promoter is conserved among
human, mouse and rat species [14]. It is thought that an
increase in intracellular cAMP concentration by AVP
stimulates the phosphorylation of CREB. Therefore, to
investigate whether AVP stimulated the phosphorylation of
CREB, cells were treated with different concentrations ofAVP. The phosphorylation of CREB was examined by
immunoblot. As shown in Fig. 6A, AVP indeed stimulated
the phosphorylation of CREB. Moreover, the addition of
forskolin, 8CPT-cAMP, or 8CPT-2Me-cAMP stimulated
CREB phosphorylation as well. These results indicate that
the activation of cAMP/Epac/ERK signaling cascade stimu-
lates the phosphorylation of CREB. Next, the effect on AVP-
stimulated CREB phosphorylation by ERK and PKA
inhibitors was investigated. Cells were pretreated with ERK
or PKA inhibitor and then incubated with AVP. AVP-
stimulated CREB phosphorylation was attenuated by ERK
inhibitor U0126, but not by PKA inhibitor Rp-cAMP (Fig.
6B). Taken together, these results indicate that AVP preferably
stimulates cAMP/Epac/ERK/CREB, but not cAMP/PKA/
CREB signaling cascade during the upregulation of AQP2
expression. A postulated regulatory mechanism of AVP-
induced AQP2 expression therefore is as follows. AVP
administration leads to the activation of Gs/adenylyl cyclase
by binding to its V2 receptor in the basolateral membrane.
This increases intracellular cAMP concentration with activa-
tion of the cAMP/Epac/ERK/CREB signaling cascade.
It is clear that the second messenger cAMP produced by AVP
action in the collecting duct principal cells is the critical factor
in regulating AQP2 expression as well as its trafficking. cAMP
regulates a variety of important biological processes such as cell
growth, differentiation, secretion and division [15,16]. Elevated
intracellular cAMP generally leads to the activation of cAMP-
dependent protein kinases (cAPKs) such as PKA [17]. To study
AQP2 trafficking in response to AVP, a number of transfected
epithelial cell culture models have been generated [3–5]. Using
Fig. 6. (A) Cells were incubated with different concentrations of AVP (10−12 to 10−8 M) for 15 min. Cell were also incubated with forskolin (10 μM), 8CPT-cAMP
(100 μM), or 8CPT-2Me-cAMP (50 μM) for 15 min. Then, cells were solubilized in lysis buffer and cell lysate was analyzed by immunoblot with phospho-CREB (p-
CREB) and CREB antibodies. Each protein blot was analyzed by densitometry. The ratio of p-CREB/CREB in basal conditions was assigned as 1-fold. (B) Cells were
pretreated without or with ERK inhibitor U0126 (10 μM) or PKA inhibitor Rp-cAMP (20 μM) for 30 min and then incubated without or with AVP (10−10 to 10−8 M)
for 15 min. Then, cells were solubilized in lysis buffer and cell lysate was analyzed by immunoblot with p-CREB and CREB antibodies. Each protein blot was
analyzed by densitometry. The ratio of p-CREB/CREB in basal conditions was assigned as 1-fold.
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that AQP2 translocation into the apical membrane occurs via
cAMP/PKA pathway, whereby the serine 256 at the C-terminus
of AQP2 is phosphorylated by the activation of PKA. It has
been also reported that in normal rats phosphorylated AQP2 is
already present in both the apical membrane and intracellular
vesicles, and there is no significant increase in phosphorylated
AQP2 after the treatment of vasopressin [18]. Further, it was
shown by oocyte expression experiments that at least three
phosphorylated AQP2 in each tetramer were required for the
insertion into the membrane [19]. These results may explain
why although phosphorylated AQP2 is already present in
intracellular vesicles of the cells, a very small PKA-induced
phosphorylation or the phosphorylation by another protein
kinase besides PKA may be needed to AQP2 trafficking.
Recent studies have indicated that cAMP does not always
mediate the activation of PKA. This suggests the possibility of a
PKA-independent regulation by cAMP. In this regard, a second
enzyme target of cAMP was discovered in 1998 [12,13]. It was
demonstrated that cAMP-activated guanine nucleotide
exchange factors (cAMP-GEFs/Epacs) directly activated Rap-
1 upon cAMP binding, which is clearly mediated by PKA-
independent activation [12,13]. However, the signaling cascade
occurring with the activation of the Epac/Rap-1 pathway is not
fully understood. Recently, a role for Epac I was identified in rat
primary cortical collecting duct cells [20]. Laroche-Joubert et al.
showed that calcitonin-induced H,K-ATPase activity was
mediated by cAMP/Epac I/Rap-1/B-Raf/ERK cascade. Thus,
cAMP targets the activation of Epac as well as PKA. To date,
the possibility of the involvement of Epac in the regulation of
AQP2 has not been investigated. In the present study it was
demonstrated that AVP-induced AQP2 expression was regu-lated in a PKA-independent manner. In this regard, AVP-
induced AQP2 expression was not blocked by PKA inhibitors
in other mouse cortical collecting duct cell line mCCDc1
(unpublished data). It is hypothesized that Epac, which is
another target of cAMP signaling, may be involved in the
regulation of AVP-induced AQP2 expression. Therefore, an
Epac specific activator 8CPT-2Me-cAMP was tested in the
present study. This cAMP analog does not stimulate PKA
activity [21]. It was demonstrated in the present study that this
Epac activator stimulated both ERK and CREB pathways.
Increased cAMP concentration after AVP administration there-
fore activated Epac/ERK/CREB signaling cascade in a PKA-
independent manner. Thus, we propose that AVP-induced
AQP2 expression is mediated via cAMP/Epac/ERK/CREB
pathway.
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